{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000474","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.223895+00:00","generated_at":"2026-06-26T04:53:48.289286+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"USANA Q1 net sales $273M (-11% YoY), EPS $1.15 (-21% YoY); cuts FY2022 guidance","bullets":["Net sales $272.9M, down 11% YoY; diluted EPS $1.15, down 21% from $1.45.","Asia Pacific net sales $218.4M (-13% YoY); Greater China down 10%; Southeast Asia Pacific down 24%.","Active customers 552,000, down 11% YoY; Americas & Europe active customers down 10%.","Revised FY2022 outlook: net sales $1.1-1.2B (was $1.125-1.225B), EPS $5.00-5.70 (was $5.25-6.00).","Company repurchased $25M in shares in Q1; $83M remaining under authorization; cites China COVID lockdowns as headwind."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000474","json":"https://secwatch.observer/filing/0001157523-22-000474.json","markdown":"https://secwatch.observer/filing/0001157523-22-000474.md","text":"https://secwatch.observer/filing/0001157523-22-000474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000474/0001157523-22-000474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000474/a52698273.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:53:48.289286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}